Regulation of transendothelial migration of Tregs in irradiated HNSCCs by EphB4-ephrinB2 interaction
EphB4-ephrinB2 相互作用对受辐射 HNSCC 中 Tregs 跨内皮迁移的调节
基本信息
- 批准号:10643984
- 负责人:
- 金额:$ 4.45万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-07-01 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:AKT Signaling PathwayAffectAnimal ModelAutoimmuneBindingBiological AssayBlood VesselsCD4 Positive T LymphocytesCD8B1 geneCell AdhesionCell CommunicationCell physiologyCellsCoculture TechniquesCombination immunotherapyCytometryCytoplasmic TailDataDiseaseEffector CellEmbryonic DevelopmentEndothelial CellsEndotheliumEphB4 ReceptorEquilibriumFOXP3 geneFailureFlow CytometryGeneticGenetic EngineeringGoalsHPV-negative head and neck cancerHead and Neck CancerHead and Neck Squamous Cell CarcinomaHomingImmuneImmune EvasionImmune checkpoint inhibitorImmunocompetentImplantInfiltrationL-SelectinLigandsLoxP-flanked alleleMalignant NeoplasmsMediatingMethodsModelingMolecularMolecular TargetMusOutcomeParticipantPathway interactionsPatientsPeptidesPhenotypePhosphorylationPhysiologicalPlayPopulationPre-Clinical ModelProcessProto-Oncogene Proteins c-aktPublishingRadiation therapyReceptor Protein-Tyrosine KinasesRegulationRegulatory T-LymphocyteResearchResistanceResistance developmentRoleSTAT3 geneSignal TransductionSiteSystemT cell differentiationT-Cell ProliferationT-LymphocyteTestingTumor PromotionUp-RegulationVascular Endothelial CellVascular Endotheliumangiogenesisanti-PD-1anti-tumor immune responsecell motilitycell typeeffective therapyeffector T cellhigh riskimmunological statusimmunoregulationin vivoinhibitorintravital microscopyknock-downmigrationmouse modelnovelpharmacologicpreclinical studyradiation responseradioresistantreceptorrecruitresponseside effecttherapy resistanttraffickingtranscriptome sequencingtumortumor growthtumor microenvironmenttumor progressiontumor-immune system interactions
项目摘要
Abstract
Resistance to radiation therapy (RT) remains a challenging problem for high-risk head and neck squamous cell
carcinoma (HNSCC) patients. Anti-PD1 is now approved in the first- and second-line settings, indicating that the
majority of these tumors are resistant to treatment. The field awaits the results of multiple trials testing whether
combining immunotherapy and RT can help avoid resistance to RT, but many preclinical studies (including those
from our lab) indicate that treatment resistance still develops despite such combinations. The preferential
recruitment of unique immunosuppressive cell subtypes after RT to the tumor microenvironment (TME) in
response to RT plays an important role in contributing to the promotion of tumor growth and progression. The
tumor endothelium can act as a selective barrier that regulates the entry, stability, and activation status of
immune cells, but the mechanistic underpinnings of this barrier activity remain poorly understood. The EphB4
receptor tyrosine kinase and its ligand ephrinB2 define novel molecular targets. Upon cell to cell contact, both
EphB4 and ephrinB2 can signal via their cytoplasmic domains. Though they have been extensively studied in
cell migration and angiogenesis in early embryonic development, little has been published on their role in
modulating the cancer immune microenvironment. Our data show that ephrinB2 is expressed on the tumor
vasculature and is upregulated by RT and that EphB4 is expressed on immunosuppressive regulatory T cells
(Tregs). Inhibiting EphB4-ephrinB2 interaction with a peptide (TNYL-RAW) results in the selective, and exclusive,
reduction in infiltration of Tregs while increasing activation of CD8+ and CD4+Foxp3- T cell populations. Tregs,
we have demonstrated, play a key role in the development of resistance to RT, and their depletion re-establishes
responsiveness to therapy in HNSCC murine models. We hypothesize that RT’s upregulation of ephrinB2 on
tumor endothelial cells acts preferentially on EphB4 expressing Tregs, and blocking this interaction reduces their
intratumoral infiltration and survival, which allows CD8+ and CD4+ effector cells to induce tumor regression. In
Aim 1, we will analyze the mechanistic outcomes of Treg EphB4 and endothelial ephrinB2 interaction on Treg
transendothelial trafficking, intratumoral homing, and survival using genetically engineered animal models with
ephrinB2 deleted on endothelial cells or EphB4 deletion on Tregs after RT. In Aim 2, we will interrogate the
cellular and molecular mechanisms triggered by the interaction between endothelial ephrinB2 and EphB4-
expressing Tregs in endothelial-Treg co-culture assays after RT. Targeted inhibition of STAT3, AKT, Erk
pathways will be done with pharmacological inhibitors based on our preliminary data. We expect that these
studies will elucidate the molecular and cellular parameters of EphB4-ephrinB2 inhibitors and will provide the
necessary information to develop a more effective therapy for RT resistant HNSCC.
抽象的
对高风险头部和颈部鳞状细胞的抗性辐射疗法(RT)仍然是一个挑战问题
癌(HNSCC)患者。抗PD1现在在一线和二线设置中获得批准,表明
这些肿瘤中的大多数对治疗有抵抗力。该领域正在等待多个试验测试的结果
结合免疫疗法和RT可以帮助避免对RT的抵抗,但是许多临床前研究(包括
从我们的实验室中)表示,治疗耐药性仍在此类组合中发展目的地。首选
RT在肿瘤微环境(TME)中募集独特的免疫抑制细胞亚型
对RT的反应在促进肿瘤生长和进展方面起着重要作用。这
肿瘤内皮可以充当调节进入,稳定性和激活状态的选择性障碍
免疫细胞,但这种屏障活性的机械基础知识仍然很少。 EPHB4
受体酪氨酸激酶及其配体ephrinb2定义了新的分子靶标。在与细胞接触的细胞接触时,两者都
Ephb4和Ephrinb2可以通过其细胞质结构域发出信号。尽管他们已经广泛研究了
细胞迁移和血管生成在早期胚胎发育中,几乎没有关于其在
调节癌症免疫微环境。我们的数据表明,ephrinb2在肿瘤上表达
脉管系统,由RT进行更新,EPHB4在免疫抑制性T细胞上表示
(Tregs)。抑制EPHB4-磷与肽(TNYL-RAW)的相互作用会导致选择性和独家,
减少Treg的浸润,同时增加CD8+和CD4+ FOXP3-T细胞种群的激活。 Tregs,
我们已经证明,在对RT的抵抗力发展中发挥关键作用,并且它们的枯竭重新建立
HNSCC鼠模型中对治疗的反应。我们假设RT在
肿瘤内皮细胞优先作用于表达Treg的EPHB4,并阻止这种相互作用减少它们
肿瘤内浸润和存活率,它允许CD8+和CD4+效应细胞诱导肿瘤消退。在
AIM 1,我们将分析Treg上Treg Ephb4和内皮Ephrinb2相互作用的机械结果
使用基因工程的动物模型,带有基因工程的动物模型
Ephrinb2在RT后在Tregs上的内皮细胞或EPHB4缺失上删除。在AIM 2中,我们将审问
由内皮ephrinb2和ephb4-之间的相互作用触发的细胞和分子机制
在RT之后,在内皮Treg共培养测定中表达Tregs。靶向抑制STAT3,AKT,ERK
根据我们的初步数据,将使用药物抑制剂来完成途径。我们希望这些
研究将阐明EPHB4-二氧化体抑制剂的分子和细胞参数,并将提供
为RT抗性HNSCC开发更有效疗法的必要信息。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Laurel B Darragh其他文献
Laurel B Darragh的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Laurel B Darragh', 18)}}的其他基金
Regulation of transendothelial migration of Tregs in irradiated HNSCCs by EphB4-ephrinB2 interaction
EphB4-ephrinB2 相互作用对受辐射 HNSCC 中 Tregs 跨内皮迁移的调节
- 批准号:
10415869 - 财政年份:2021
- 资助金额:
$ 4.45万 - 项目类别:
Regulation of transendothelial migration of Tregs in irradiated HNSCCs by EphB4-ephrinB2 interaction
EphB4-ephrinB2 相互作用对受辐射 HNSCC 中 Tregs 跨内皮迁移的调节
- 批准号:
10315419 - 财政年份:2021
- 资助金额:
$ 4.45万 - 项目类别:
相似国自然基金
肾—骨应答调控骨骼VDR/RXR对糖尿病肾病动物模型FGF23分泌的影响及中药的干预作用
- 批准号:82074395
- 批准年份:2020
- 资助金额:55 万元
- 项目类别:面上项目
基于细胞自噬调控的苦参碱对多囊肾小鼠动物模型肾囊肿形成的影响和机制研究
- 批准号:
- 批准年份:2019
- 资助金额:33 万元
- 项目类别:地区科学基金项目
NRSF表达水平对抑郁模型小鼠行为的影响及其分子机制研究
- 批准号:81801333
- 批准年份:2018
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
靶向诱导merlin/p53协同性亚细胞穿梭对听神经瘤在体生长的影响
- 批准号:81800898
- 批准年份:2018
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
伪狂犬病病毒激活三叉神经节细胞对其NF-кB和PI3K/Akt信号转导通路影响的分子机制研究
- 批准号:31860716
- 批准年份:2018
- 资助金额:39.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Harnessing Cells from Human Milk; Linking Lactation to Metabolism
利用人乳细胞;
- 批准号:
10348599 - 财政年份:2022
- 资助金额:
$ 4.45万 - 项目类别:
Identification and Imaging of Skeletal Muscle Response to Graded Nerve Crush
骨骼肌对分级神经挤压反应的识别和成像
- 批准号:
10646172 - 财政年份:2022
- 资助金额:
$ 4.45万 - 项目类别:
The cellular molecular regulation of differing mechanisms of insulin resistance.
胰岛素抵抗不同机制的细胞分子调节。
- 批准号:
10531044 - 财政年份:2022
- 资助金额:
$ 4.45万 - 项目类别:
Identification and Imaging of Skeletal Muscle Response to Graded Nerve Crush
骨骼肌对分级神经挤压反应的识别和成像
- 批准号:
10351778 - 财政年份:2022
- 资助金额:
$ 4.45万 - 项目类别:
Harnessing Cells from Human Milk; Linking Lactation to Metabolism
利用人乳细胞;
- 批准号:
10670056 - 财政年份:2022
- 资助金额:
$ 4.45万 - 项目类别: